Condition: Diabetic Macular Edema · Macular Edema · Type 2 Diabetes With Diabetic Macular Edema · Sponsor: Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.
This description comes directly from the study's public registry record.
Ling Yang · +8613421382136 · yangling@relin.cn
Always discuss trial participation with your own doctor first.
| The Second Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Shanghai General Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04187443